Novavax Inc (NVAX.O) announced on Monday that it had sought for U.S. approval to use its COVID-19 vaccine as a booster dose in persons who have previously received it or another vaccine.
The application to the US Food and Drug Administration comes amid a slow rollout in the US, where the Novavax vaccine was approved in July, despite anticipation that it would persuade vaccine doubters to become immunized.
The Novavax vaccine, which uses conventional technology, is crucial for individuals to have as they consider how to remain protected against COVID-19, according to Chief Executive Officer Stanley Erck in a statement.
It is a protein-based vaccination that uses pure virus fragments to activate the immune system; this technique has been employed to fight diseases including hepatitis B and influenza.
Out of the 606 million doses that have been provided worldwide, over 9,700 doses of the vaccine have already been given in the United States. The most recent federal data show that more than 67% of Americans have had two doses of the COVID-19 vaccine.
Due to a supply glut and weak demand, the business last week cut its full-year revenue target because it doesn’t anticipate any major sales of its COVID-19 shot in the United States this year.
Shares of Novavax increased by 2% to $42.31 before the opening bell.
 announced on Monday that it had sought for U.S. approval to use its COVID-19 vaccine as a booster dose in persons who have previously received it or another vaccine.){kind=link}